GENT Stock Overview
Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Gentian Diagnostics ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr37.60 |
| 52 Week High | kr49.90 |
| 52 Week Low | kr34.80 |
| Beta | 0.61 |
| 1 Month Change | -6.70% |
| 3 Month Change | -13.16% |
| 1 Year Change | -24.04% |
| 3 Year Change | -30.88% |
| 5 Year Change | -32.37% |
| Change since IPO | 44.62% |
Recent News & Updates
Recent updates
Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report
Feb 14
Here's Why We're Not At All Concerned With Gentian Diagnostics' (OB:GENT) Cash Burn Situation
Oct 28We're Not Worried About Gentian Diagnostics' (OB:GENT) Cash Burn
May 11Can You Imagine How Gentian Diagnostics' (OB:GENT) Shareholders Feel About The 57% Share Price Increase?
Mar 20What Percentage Of Gentian Diagnostics AS (OB:GENT) Shares Do Insiders Own?
Feb 21Have Insiders Been Selling Gentian Diagnostics AS (OB:GENT) Shares?
Jan 17
Gentian Diagnostics AS (OB:GENT): When Will It Breakeven?
Dec 14Shareholder Returns
| GENT | NO Medical Equipment | NO Market | |
|---|---|---|---|
| 7D | 4.4% | 0.6% | -0.5% |
| 1Y | -24.0% | 1.1% | 2.9% |
Return vs Industry: GENT underperformed the Norwegian Medical Equipment industry which returned 1.1% over the past year.
Return vs Market: GENT underperformed the Norwegian Market which returned 2.9% over the past year.
Price Volatility
| GENT volatility | |
|---|---|
| GENT Average Weekly Movement | 4.8% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in NO Market | 10.5% |
| 10% least volatile stocks in NO Market | 2.9% |
Stable Share Price: GENT has not had significant price volatility in the past 3 months.
Volatility Over Time: GENT's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 58 | Hilja Ibert | www.gentian.com |
Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research worldwide. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric immunoassay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a glomerular filtration rate marker for the diagnosis and therapeutic control of renal function; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and canine CRP immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. It also provides SARS-CoV-2 total antibody immunoassay, quantitative antibody test captures the full immune response detecting antibodies targeting the S1-subunit.
Gentian Diagnostics ASA Fundamentals Summary
| GENT fundamental statistics | |
|---|---|
| Market cap | kr579.88m |
| Earnings (TTM) | -kr10.65m |
| Revenue (TTM) | kr142.35m |
4.1x
P/S Ratio-54.5x
P/E RatioIs GENT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GENT income statement (TTM) | |
|---|---|
| Revenue | kr142.35m |
| Cost of Revenue | kr66.75m |
| Gross Profit | kr75.60m |
| Other Expenses | kr86.24m |
| Earnings | -kr10.65m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.69 |
| Gross Margin | 53.11% |
| Net Profit Margin | -7.48% |
| Debt/Equity Ratio | 0% |
How did GENT perform over the long term?
See historical performance and comparison